COLLPLANT BIOTECH. IS-01 (CPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has a cash flow conversion efficiency ratio of -0.483x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.94 Million ≈ $-3.43 Million USD) by net assets (€6.08 Million ≈ $7.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CPT equity to assets ratio to measure how much of total assets are equity-financed.
COLLPLANT BIOTECH. IS-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COLLPLANT BIOTECH. IS-01 (CPT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
COLLPLANT BIOTECH. IS-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lomiko Metals Inc
V:LMR
|
-0.093x |
|
Bank Maybank Indonesia Tbk PT
JK:BNII
|
0.000x |
|
Sonim Technologies Inc
NASDAQ:SONM
|
0.298x |
|
Gratomic Inc
V:GRAT
|
-0.003x |
|
Binani Industries Limited
NSE:BINANIIND
|
0.019x |
|
MOVIE GAMES S.A. ZY1
F:2LH
|
0.070x |
|
Dunedin Income Growth Investment Trust PLC
LSE:DIG
|
0.016x |
|
Munic SA
PA:ALMUN
|
0.112x |
Annual Cash Flow Conversion Efficiency for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of COLLPLANT BIOTECH. IS-01.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
€-9.42 Million ≈ $-11.01 Million |
-1.549x | -47.99% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
€-14.09 Million ≈ $-16.48 Million |
-1.047x | -973.53% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
€-2.76 Million ≈ $-3.23 Million |
-0.097x | +77.02% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
€-13.70 Million ≈ $-16.01 Million |
-0.424x | -865.55% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
€2.50 Million ≈ $2.92 Million |
0.055x | -- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more